ABSTRACT Computational drug repositioning plays a vital role in the prediction of drug function. Many new functions discovered have been confirmed. In comparison with traditional drug repositioning, computational drug repositioning shortens the time and reduces labor. Thus, it has received wide attention in recent years. However, prediction remains a considerable challenge. In this paper, a method called HNRD is introduced to predict the link between drugs and diseases. It is based on neighborhood information aggregation in neural networks which combines the similarity of diseases and drugs, the associations between the drugs and diseases. Compared with the state-of-the-art method before, our method has achieved better results, with the best AUC of 0.97 in one of the golden datasets. To better evaluate our approach, we also performed data analysis based on one-to-one association's prediction and robust analysis by testing on different datasets. All the results prove the excellent performance of prediction. Source codes of this paper are available on https://github.com/heibaipei/HNRD. INDEX TERMS Drug reposition, deep learning, matrix decomposition, heterogeneous network, end to end.
I. INTRODUCTION
Drug research and development is a complex, lengthy and expensive process. It often takes 10-15 years of research and 0.8-15 billion dollars to make a drug from abstract concept to market-ready product [1] . Annually, 90% of drugs fail to get access to FDA evaluations, thereby preventing their use in actual therapy [2] - [5] . Accordingly, Drug Repositioning (DR) based on computing method appears. The repositioning method bypasses many pre-approval tests that are critical to newly developed therapeutic compounds, and it can shorten the drug development cycle to 3-12 years for a repositioned drug [6] . In recent years, DR has received increased interest from governments, nongovernmental agencies and academic researchers.
In general, DR seeks to find new uses for existing drugs, with established and demonstrated human safety. In technical terminology, DR is the process by which new indications are found for approved drugs [7] . Recently, the usage The associate editor coordinating the review of this manuscript and approving it for publication was Ying Song. of computational DR in drug discovery has become a popular practice, and an increasing number of machine learning [8] - [10] , network analysis [11] - [13] , text mining and semantic inference methods [14] have been proposed [15] - [20] .
PREDICT [21] calculates the link between potential drugs and diseases, mainly by integrating the similarities between various drugs, diseases, and using these features to obtain new potential features through a logical classifier. DRRS [22] merges three matrices, including the drug similarity matrix, the disease similarity matrix, and the drug and disease association matrix, into one large matrix. Then it finds the lowest level of the big matrix that reconstructs the large matrix. NeoDTI [23] predicts new drugs and drug targets by integrating various information in heterogeneous networks and conducting end-to-end learning through a nonlinear model. TL-HGBI [24] has proposed a computational framework, to infer novel treatments for diseases based on a heterogeneous network integrating similarity and association data about diseases, drugs and drug targets. DrugNet [25] has FIGURE 1. HNDR flowchart: (a) Input data include a reconstructive drug-drug similarity matrix, a disease semantic similarity matrix, and an experimentally verified drug-disease association matrix. The similarity matrices are symmetric. (b) Construct a heterogeneous network. Each node of the network is either drug or disease and is initialized with a low dimensional vector representation. (c) Perform neighborhood information integration, which updates nodes representation. (d) Reconstruct three matrices with learned node representation. These three new matrices serve the next input of feature extraction procedure. The procedure is designed to minimize the difference between the initial matrices and reconstructed matrices, the reconstructed drug-disease matrix is used to predict potential associations between drugs and diseases.
developed a network-based prioritization method to predict new therapeutic indications for drugs and novel treatments for diseases. This method identifies novel drug-disease associations by propagating information in a heterogeneous network which is constructed by using all the information about diseases. Reference [26] integrates miRNA similarity and disease similarity based on the functional similarity of miRNA, disease semantic similarity and Gaussian interaction profile kernel similarity, and predicts the association between miRNA and disease through inductive matrix completion. Reference [27] has proposed MBiRW utilizing some comprehensive similarity measures, and Bi-Random walk (BiRW) algorithm to identify potential novel indications for a given drug. By integrating information about drug or disease features with known drug-disease associations, the comprehensive similarity measures are initially developed to calculate the similarity between drugs and diseases, which has demonstrated certain success in computational DR, and other drug or disease association [28] - [35] . Although some of these methods are predictions of the potential relationship between drugs and drug targets [36] , [37] , all methods prove that multiple relationships integrated into a graph could improve the effect of prediction novel link.
Inspired by currently popular neural-network-based approaches, we introduce a neural-network-based method of neural-network-based integration of neighborhood information in a Heterogeneous Network for drug-Disease association prediction (HNRD) in this paper to predict novel associations between drug and disease. In the HNRD, a heterogeneous network is first generated from the dataset with each node, either drug or disease, by integrating neighborhood information, which is achieved through the nonlinear feature learning. Then, HNRD enforces the embedding node representations of drugs and diseases to match the observed matrices. HNRD is a global approach that can rank candidate drug-disease pairs for all diseases simultaneously. In tenfold cross-validation experiments, our method achieves an area under the receiver operating characteristic curve (AUC) of 0.97 in one of the golden datasets, which is approximately higher than that of the state-of-the-art method. Additionally, we perform leave-one-out cross-validation (LOOCV) experiments based on the new drug prediction where only one association exits drug and disease; our method achieves a perfect result, which is approximately 2% higher than the state-of-the-art method we know. Finally, to further prove the validation we use different dataset with our algorithm.
The main contribution of this paper involves the following: (1) our proposed method preformed a deep network to extract drug features from the drug-drug matrix and the drug-disease matrix, to extract disease features from the disease matrix and disease-drug matrix, finally, based on the principle of matrix decomposition, the two recessive features are decomposed as the matrix to recover the matrix. It is the first time to apply in the drug-disease reposition using the end-to-end method to recover method. (2) Considering the characters of the network model, large data is needed to train the model. A large amount of data corresponds to a good AUC. Among the datasets, the DNdataset has the biggest matrix, which has the highest AUC of 0.972. Its precision rate can reach 0.802, which is much higher than that of the state-of-the-art method with an AUC of 0.935 and maximum precision is 0.348. It would not be influenced by the sparse as long as the amount of data is abundant.
II. MATERIALS AND METHODS
In this study, we propose a novel DR HNRD approach to infer potential drug indications. First, we provide a brief description of our datasets. Then, HNRD is utilized to train the prediction model to predict the missing association in the test dataset.
A. DATASETS
The gold standard dataset include three apartments. For the drug-drug similarity matrix, the chemical structure of all drugs are download from DrugBank in the Canonical Simplified Molecular-Input Line-Entry System (SMILES) format [38] , and then a two-category is calculated according to the Chemical Development Kit [39] . Finally, based on the two fingerprints the similarity is calculated, with a range of [0, 1] .
For the disease-disease similarity matrix, a phenotypebased disease-disease similarity dataset is downloaded from MimMiner [40] , which was constructed by calculating similarities based on the numbers of occurrences of Medical Subject Headings vocabulary (MeSH) terms in the medical descriptions of each pair of diseases from the OMIM database [41] . According to the MimMiner database description, the similarities have already been normalized to the range [0, 1].
For the drug-disease matrix, initial disease drug interactions were obtained from [21] , where disease and drug interactions are assembled for the diseases listed in the OMIM database and their associated drugs but are limited to the ones registered in the DrugBank database [42] . The corresponding value in the matrix W dr was set to 1 if an interaction exists and 0 otherwise.
B. SCHEMATIC OVERVIEW OF HNRD
a) Construct a heterogeneous network based on three standard matrices. The three matrices mainly include the drug similarity link matrix, the disease similarity adjacency matrix, and the correlation matrix of drugs and diseases. The similarity matrix is symmetrical, whereas the drug-disease correlation matrix is asymmetric and binary. Regularize the correlation matrix for each pair. b) Integrate neighborhood information for drugs and diseases, and embed low-dimensional space, each with a low-dimensional representation. c) Reconstruct the drug-disease matrices with the captured feature vectors. This step is intended to minimize the different between the reconstructed matrices and the initial matrices. It also can be considered as an embedding process to maximize the extraction of information about the three matrices. e) Finally, predict the drug-disease sequence by reconstructing the matrix. The whole task can be considered as a filling of the matrix, mainly to fill the data that is not in the part [43] .
C. HETEROGENEOUS NETWORK
Let S rr R m×m be the drug expression profile similarity matrix and S dd R n×n be the similarity matrix between diseases. Let A R m×n be the drug-disease association matrix, where for each number a ij in A, a ij = 1 if drug (i) is connected to disease (j) , otherwise, a ij = 0. Elements of each matrix are non-negative. For each matrix, we conduct normalization before further processing. Let S rr , S dd , A be the normalized matrix of drug expression profile similarity matrix, disease semantic similarity matrix and drug-disease associations matrix, respectively such that:
where M stands for matrix and num(col) is the size of the matrix's column dimension. By using the normalized matrices as edges weight, a heterogeneous network is generated which contains two node types {drug, disease} and three edge types {drug-drug, disease-disease, drug-disease}.
D. NODE EMBEDDING
For each node v, drug or disease. Its features should be aggregated from its neighbors, which have a positive weight of connections between node v and its neighbors:
where R ei R 2d and D ei R 2d are the embeddings of drug i and disease i , respectively. The initial representations of nodes (R ei R d or D ei R d ) are randomly set. Through neighborhood aggregation, we obtain the representation of each node, considering its relation with its neighbor nodes considering its connection and its own nodes features, and we learn the structural and topological information as the feature vectors σ j xy is defined as follows:
where W and b are parameters trained in the neural network. 0) ) stands for the activation function in the neural network. In this step, the model further learns node representations into lower dimensional vectors and implement normalization:
where e i stands for either R ei or D ei . In this step, a new embedding is learned in a single-layer neural network which non-linearly transforms the representation of the nodes.
E. TRAINING AND EVALUATION
We train the neural network to minimize losses between reconstructed matrices and the initial matrices.
Here E R d×k functions as projection matrices, which extract the principle features from node representations. The inner product of the two projected vectors should be reconstructed by the original edge weights as much as possible. For a symmetric matrix reconstruction ( drug-drug similarity matrix or disease-disease similarity matrix), the matrix EE T is used to enforce symmetry of the recovery. A similar reconstruction strategy has also been used [44] to solve prediction problems.
Considering that all operations are differentiable and sub differentiable, parameters can be trained in an end-to-end manner by performing gradient descent. After training, each LDA score could be predicted using the reconstructed drugdisease association matrix. A high score corresponds to a high probability, and we suggest that the following potential association exists:
In this sense, the HNRD prediction task can be considered as a matrix completion problem, which is conventionally solved by matrix factorization with mathematical calculation. By comparison, our method develops a deep learning model to generate feature matrices by explicitly defining the construction process. Through representation learning, HNRD incorporates prior knowledge of network topology, after which the loss minimization procedure is implemented to prevent the network from being arbitrarily factorized. As a result, the method obtains performance improvement in identifying LDA associations.
III. RESULTS
In this section, we systematically evaluate the performance of HNRD by using the datasets. First, the evaluation metrics used in this study are introduced. Then, we compare HNRD with several other methods in terms of prioritizing candidate diseases for a given drug. Next, a case study is conducted to further illustrate the practical usefulness of HNRD. Finally, we perform prediction on the other dataset to verify the robustness of our method.
A. EVALUATION METRICS
To evaluate the effect of HNRD on DR, a ten-fold crossvalidation was used. The gold has links to 1933 already known and other unverified links. All known links and the unverified data set are randomly divided into 10, from each of the positive and negative samples as a testset, and the rest as training sets.
When the probability of connection between the drug and disease is re-estimated, the tested links and the candidate links are reordered for each drug. For each specific threshold, four values of true positive (TP), false positive (FP), false negative (FN), and true negative (TN) are calculated [45] - [47] . Predicted value ranks that exceed the threshold are considered correct. TP and TN indicates that the positive and negative samples are correctly predicted, and FN and FP are predicted to be incorrect for the positive and negative samples, respectively. The TPR, FPR, and correct rate are calculated by varying thresholds, resulting in the Receiver Operating Characteristic (ROC) and Precision Rate(PR). For the ROC curve, FPR and TPR are plotted on the x-axis and y-axis, respectively. For PR curve, recall is plotted on the x-axis, and precision is plotted on the y-axis [48] . The area under ROC curve (AUC) value and precision are utilized to evaluate the overall performance of the prediction methods. PR does not represent the preparation rate, but only the existing link probability is ranked first, and the position is ranked later.
B. COMPARISON WITH OTHER METHODS
To assess the performance of HNRD, we compare it with the other five methods: DRRS [22] , MBiRW [27] , DrugNet [25] , HGBI [24] , and KBMF [49] . DRRS constructs a big matrix combine the drug-drug similarity, disease-disease similarity and drug-disease matrix, and finds the minimum rank to reconstruct the drug-disease matrix. MBiRW utilizes the comprehensive similarity measures and Bi-Random Walk algorithm to identify potential novel indications for the given drug. DrugNet is a generic network-based drug repositioning method, which propagates information between networks and can be used to perform both drug-disease and diseasedrug. HGBI is introduced based on the guilt-by-association principle and an intuitive interpretation of information flow on the heterogeneous graph. All the parameters used in these methods are determined according to their literature. KBMF is a kernelized Bayesian matrix factorization method, that may work with multiple data side information and can be applied in recommendation systems, the parameter R used as 40 is the same as DRRS. The overall performance of all methods is evaluated by applying ten-fold cross-validation. The experiment results in terms of ROC curves and PR curves are depicted in Figure2. Experiment results show that our proposed method outperforms other competitive methods in terms of AUC and precision values. HNRD can achieve an AUC value of 0.942, while the best precision can be 0.572, indicating that it can successfully prioritize 57.2% true drug-disease associations as the ones with the highest rank.
C. PREDICTING INDICATIONS FOR NEW DRUGS
LOOCV was implemented on the known experimentally verified drug-disease associations to evaluate the performance of HNRD. For a given disease d i , each known drug associated to d i is left out in turn as the test sample, while the other known experimentally verified drugs associated with d i are considered as training samples. All the drugs without known associations with d i make up the d i -associated candidate samples. In the candidate samples, the test sample is deemed as a positive sample, and the others are negative samples. In each turn, predicting score was recovered by the HNRD method. After all drug-disease entries have been predicted, a special ranking 
D. HNRD PREDICTS NOVEL RD
After confirming the prediction ability of HNDR by crossvalidation experiments, we conducted a comprehensive prediction of novel associations between all drugs and diseases.
In the inference process, all known drug-disease associations in the gold standard dataset are used as the training set and the remaining drug disease pairs are regarded as the set of candidate drug-disease associations. HNRD can predict the potential disease associations for all drugs simultaneously. By applying HNRD, all candidate diseases for a specific drug are ranked according to their predicted values assigned by HNRD. We also have conducted case studies to verify whether the predicted top-ranked diseases are true or not according to two public biological databases: KEGG [50] and CTD [51] , which have been constantly updated to include newly verified drug-disease associations and provide a foundation for our validation. We examined the most potential indications for each of the 593 drugs. The predicted results by all methods are summarized in Supplementary form S1. One can observe that 160 of top-5 predicted novel drugdisease associations by HNRD have been annotated in KEGG and CTD, respectively, which are more than the other prediction methods. We choose several drugs as examples and list the verified information of the top-5 candidate diseases for each selected drug in Supplementary Tables S2. We find several novel drug disease associations of the top-ranked predictions that have been annotated in KEGG, CTD or the other papers. For example Esophageal cancer is cancer arising from the esophagus-the food pipe that runs between the throat and the stomach [52] . Topotecan is a semi-synthetic derivative of camptothecin. Camptothecin is a natural product extracted from the bark of the tree Camptotheca acuminata. Topoisomerase-I is a nuclear enzyme that relieves torsional strain in DNA by opening single strand breaks [53] . Once topoisomerase-I creates a single strand break, the DNA can rotate in front of the advancing replication fork. In physiological environments, topotecan is in equilibrium with its inactive carboxylate form [54] , so it also can be used in Esophageal cancer by the same function.
E. VALIDATION ON THE OTHER DATASETS
To demonstrate the capability of HNRD in predicting new drugs related to a queried disease, we also conduct some test on other datasets, including Cdataset and DNdataset, which have been used in the research [27] . Cdataset includes 663 drugs registered in DrugBank, 409 diseases listed in OMIM database, and 2,353 verified drug-disease associations. DNdataset contains 4,516 diseases annotated by Disease Ontology (DO) terms, 1,490 drugs registered in DrugBank and 1008 known drug-disease associations derived from DrugBank.
We conduct ten times ten-fold cross-validation to validate the prediction accuracy of our proposed method on Cdataset and DNdataset. HNRD achieves an AUC value of 0.95 in the Ddataset whereas DRRS, MBiRW, HGBI, DrugNet and KBMF obtain inferior results of 0.947, 0.933, 0.858, 0.804 and 0.928, respectively. The maximum precision achieved by HNRD is 0.67, which is higher than that of the other methods. The AUC value obtained by HNRD is 0.97 in the Dndataset, which is higher than that obtained by DRRS, MBiRW and DrugNet. This may be due to the larger size than the other datasets.
IV. DISCUSSION AND CONCLUSION
Identifying the relationships between drugs and diseases is essential for understanding the mechanisms and functions of drugs. In this paper, we apply a neural-network-based model to predict drug-disease associations. LOOCV and case studies are implemented to evaluate the performance of our method in comparison with the other state-of-the-art approaches. In comparison with the state-of-the-art method, HNRD performs better in terms of AUC values on the dataset and can retrieve more correct associations. Results show that HNRD could be a useful tool for studying the drugdisease relationship. We analyze the top 5 predictions by using HNRD. In the case studies, we confirm drug connections with gastric, ovarian, and colorectal cancer by literature mining. Our study has a major contribution in identifying potential drug-disease associations that our method could integrate more matrix than we have integrated (e.g., drug Gaussian kernel similarity matrix) due to its property of heterogeneity.
The basic idea of considering drug-disease prediction problem as a matrix factorization problem is to determine a low-rank matrix that can integrate prior knowledge about drug and disease. Multiple methods have been proposed and then improved for the task. Therefore, our method might be improved in the future. Considering that matrix factorization is often applied in small data, when the number of data increases, the time consumed is very long. However, HNRD is generated from the neural network, which needs sufficient data. As time passes, the dataset will be updated, and the model will be friendlier to predict. 
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